Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 778-787

  Koleganova, Nadezda ^a   Piecha, Grzegorz ^a,b   Ritz, Eberhard ^a   Gross, Marie Luise ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Calcitriol; Cardiac remodelling; Chronic renal failure; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

3 NITROTYROSINE; CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHORUS; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VITAMIN D RECEPTOR;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CALCIUM METABOLISM; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE FIBROSIS; HEART WEIGHT; INTERSTITIUM; MALE; MICROANGIOPATHY; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; CALCITRIOL; CAPILLARIES; DISEASE MODELS, ANIMAL; FIBROSIS; HEART DISEASES; KIDNEY FAILURE, CHRONIC; MALE; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING; VITAMINS;

EID: 60749099438     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn549     Document Type: Article

References (40)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
2. Amann K, Breitbach M, Ritz E et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9: 1018-1022
3. Amann K, Kronenberg G, Gehlen F et al. Cardiac remodelling in experimental renal failure - an immunohistochemical study. Nephrol Dial Transplant 1998; 13: 1958-1966
4. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008; 11: 7-12
5. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
6. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
7. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132
8. Wu J, Garami M, Cheng T et al. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588
9. Nibbelink KA, Tishkoff DX, Hershey SD et al. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiacmyocyte. J Steroid Biochem Mol Biol 2007; 103: 533-537
10. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci 2007; 104: 16810-16815
11. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238
12. Piecha G, Kokeny G, Nakagawa K et al. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 2008; 294: F748-F757
13. Gross M-L, Ritz E, Korsch M et al. Effects of estrogens on cardiovascular structure in uninephrectomized SHRsp rats. Kidney Int 2005; 67: 849-857
14. Henquell L, Honig C. Intercapillary distances and capillary reserve in right and left ventricles: significance for control of tissue pO2. Microvasc Res 1976; 12: 35-41
15. Amann K, Tornig J, Flechtenmacher C et al. Blood-pressure- independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant 1995; 10: 2043-2048
16. Park C, Oh Y, Shin Y et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81
17. Kuhlmann A, Haas CS, Gross M-L et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533
18. Korkor AB. Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987; 316: 1573-1577
19. Martínez J, Olmos JM, de Francisco AL et al. 1,25-Dihydroxyvitamin D3 receptors in peripheral blood mononuclear cells from patients with primary and secondary hyperparathyroidism. Bone Miner 1994; 27: 25-32
20. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571
21. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828
22. Sasso FC, Torella D, Carbonara O et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005; 46: 827-834
23. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356: 830-840
24. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007; 9: 546-550
25. Kass DA, Bronzwaer JGF, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94: 1533-1542
26. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95: 754-763
27. Ahmed SH, Clark LL, Pennington WR et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096
28. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
29. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 2008 Jun 26. [Epub ahead of print]
30. Thannickal VJ, Day RM, Klinz SG et al. Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-beta1. Faseb J 2000; 14: 1741-1748
31. Iglarz M, Touyz RM, Viel EC et al. Peroxisome proliferator- activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42: 737-743
32. Ogata T, Miyauchi T, Sakai S et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-1488
33. Sakuma T, Miyamoto T, Jiang W et al. Inhibition of peroxisome proliferator-activated receptor alpha signaling by vitamin D receptor. Biochem Biophys Res Commun 2003; 312: 513-519
34. Opie LH, Commerford PJ, Gersh BJ et al. Controversies in ventricular remodelling. Lancet 2006; 367: 356-367
35. Selvetella G, Hirsch E, Notte A et al. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 2004; 63: 373-380
36. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007; 116: 1413-1423
37. Bueno OF, De Windt LJ, Tymitz KM et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000; 19: 6341-6350
38. Amann K, Ritz E, Wiest G et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819
39. Ogata H, Ritz E, Odoni G et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14: 959-967
40. Repo JM, Rantala IS, Honkanen TT et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007; 72: 977-984